Brain Cancer Diagnostics Market (2025 - 2033) Size, Share & Trends Analysis Report By Product (Reagents & Consumables, Software & AI Solutions), By Technique (Imaging, Molecular Diagnostics), By Cancer Type, By End Use, By Region, And Segment Forecasts

Brain Cancer Diagnostics Market Summary

The Brain cancer diagnostics market size was valued at USD 1.61 billion in 2024 and is expected to reach USD 3.06 billion by 2033, growing at a CAGR of 7.60% from 2025 to 2033. The market growth is driven by the rising global incidence of primary and metastatic brain tumors, coupled with the need for early and accurate detection to guide complex treatment decisions.

Growing adoption of advanced imaging modalities (MRI, PET-MRI), integration of molecular profiling into WHO and NCCN guidelines, and the increasing role of AI-enabled platforms are fueling market growth. In addition, expanding reimbursement for DNA methylation profiling and heightened patient advocacy initiatives are accelerating access, standardization, and demand for innovative diagnostic solutions.

The global brain cancer diagnostics industry represents a high-value, high-need opportunity at the intersection of oncology and advanced diagnostics. Although brain cancers account for just ~2% of all cancers, they rank among the most burdensome malignancies worldwide, driving the fourth highest number of years of life lost across cancers. Treatment costs are exceptionally high, and patients typically undergo lifelong surveillance and follow-up scans. Importantly, until recently, brain tumors were the leading cause of cancer-related death among pediatric and young adult patients, underscoring the unmet medical need.

From a market perspective, this unique disease burden translates into sustained demand for diagnostics. The clinical reality is that therapeutic innovation in brain tumors has lagged behind other cancers; as a result, patient management is disproportionately dependent on accurate, repeated, and advanced diagnostics.

Complexity in Diagnosis - Market Implications

Brain cancers are not a single disease but a heterogeneous group with over 120 molecular subtypes, each requiring distinct diagnostic and treatment strategies. For providers, this creates a critical dependence on specialized pathology and advanced testing. Traditional techniques such as immunohistochemistry and microscopy remain standard, but they are limited by high error rates and intraclass variability.

Evidence highlights the commercial opportunity for advanced methods. A prospective study profiling nearly 2,000 brain tumors showed that visual diagnosis misclassified 14% of cases, while a landmark pediatric trial failed when 74% of patients were later reclassified. For industry stakeholders, this highlights a clear demand for next-generation solutions that minimize diagnostic error and ensure correct treatment allocation.

DNA Methylation Profiling - A Transformative Technology

One of the most significant breakthroughs in the last decade has been DNA methylation profiling. This molecular approach generates a tumor “fingerprint,” enabling objective classification, prognosis, and therapy guidance. The German Cancer Research Center (DKFZ), in collaboration with NYU Langone, developed the Heidelberg Brain Tumour Classifier, now integrated into WHO CNS classification guidelines and recommended by the NCCN.

The market significance is clear: in 2024, the American Medical Association approved a CPT reimbursement code for methylation profiling in the U.S., a milestone that is expected to accelerate adoption. Prior to this, reimbursement was a major barrier, restricting access to elite centers and philanthropic support. With reimbursement secured, methylation testing is poised to shift from niche to mainstream, opening new revenue opportunities for diagnostics companies, service labs, and technology vendors.

Technology Landscape and Competitive Positioning

• Imaging Systems remain the backbone, representing the largest revenue share. MRI and PET-MRI are essential for initial diagnosis and monitoring. Leading players such as GE Healthcare, Siemens Healthineers, and Philips Healthcare continue to innovate with high-resolution imaging and AI integration.

• Molecular Diagnostics is the fastest-growing subsegment, driven by methylation profiling, sequencing panels, and emerging liquid biopsy approaches for glioblastoma. Market leaders include Illumina, Thermo Fisher Scientific, Roche Diagnostics, and Agilent Technologies.

• AI and Digital Pathology solutions, such as Philips IntelliSpace and PathAI, are enhancing accuracy, particularly in under-resourced healthcare settings where access to neuropathologists is limited.

• Research-driven Models are proving commercial viability. For example, deep learning applied to the Bangladesh Brain Cancer MRI dataset demonstrated near-perfect accuracy (>99%) using DenseNet169, signaling strong potential for scalable, lower-cost diagnostic support.

Patient Advocacy, Awareness, and Market Expansion

Patient organizations are directly influencing diagnostic adoption. The End Brain Cancer Initiative (EBCI) launched a mobile app in 2022, providing education on symptoms, genomic testing, clinical trials, and care pathways, bridging access gaps and supporting faster adoption of advanced diagnostics. Similarly, campaigns such as Brain Tumour Awareness Month in Canada drive funding, awareness, and patient engagement, all of which fuel diagnostic utilization.

The burden of brain tumors in the United States continues to rise, reinforcing the need for accurate diagnostics and innovative care solutions. In 2025, it is estimated that over 1.3 million Americans are living with a primary brain tumor, reflecting both improved survivorship and the chronic nature of disease management. Each year, thousands of new patients add to this pool, creating a sustained demand for diagnostic services, follow-up monitoring, and supportive care.

In terms of incidence, approximately 93,000 new cases of primary brain tumors are projected in 2025. Of these, around 24,000 are malignant, underscoring the significant clinical challenge posed by aggressive tumors such as glioblastoma, astrocytomas, and primary CNS lymphomas. Malignant brain tumors remain among the deadliest cancers, with a relative survival rate of just 35.7%, one of the lowest across all oncology indications.

Mortality continues to impose a heavy toll. In 2025, an estimated 18,300 Americans are expected to die from malignant brain tumors. This figure highlights not only the lethality of the disease but also the continued lack of meaningful therapeutic breakthroughs compared to other cancer types, where survival rates have markedly improved.

For stakeholders in the diagnostics market, these statistics translate into a consistent and growing demand for solutions across the diagnostic continuum,  from imaging and biopsy to molecular profiling and liquid biopsy. The sheer number of patients requiring initial diagnosis, recurrence monitoring, and long-term surveillance underscores why diagnostics represent nearly half of the overall brain tumor market.

Despite heavy research into glioblastoma, one of the most sequenced tumors in oncology, therapeutic progress has been minimal for nearly two decades. This creates a structural dependency on diagnostics, not just for initial identification, but for recurrence monitoring, trial enrollment, and patient management across the care continuum.

Market Concentration & Characteristics

The brain cancer diagnostics market demonstrates a high degree of innovation, particularly with the integration of molecular profiling, DNA methylation assays, and AI-driven imaging platforms. Traditional imaging modalities like MRI and CT remain foundational, but next-generation sequencing, liquid biopsy, and digital pathology are expanding diagnostic accuracy. Continuous R&D by major players such as Illumina, Thermo Fisher, and Philips accelerates precision medicine adoption. Innovation is also fueled by academic-industry collaborations and the growing incorporation of novel biomarkers into the WHO CNS tumor guidelines.

The market reflects moderate-to-high merger and acquisition activity, as companies pursue consolidation to strengthen diagnostic portfolios. Large imaging players like Siemens Healthineers and GE Healthcare frequently acquire AI startups to integrate software solutions into imaging systems. Similarly, molecular diagnostic leaders such as Roche and Illumina expand through strategic deals, ensuring access to next-gen sequencing tools and companion diagnostics. These M&As are driven by the need for end-to-end diagnostic ecosystems, where imaging, molecular testing, and digital tools converge to improve patient outcomes and capture long-term market share.

Regulation plays a critical role in shaping the brain cancer diagnostics industry. The U.S. approvals, such as CLIA certification and CPT codes for DNA methylation profiling, have accelerated adoption by ensuring reimbursement pathways. The World Health Organization’s classification system now mandates molecular profiling for accurate CNS tumor typing, pushing diagnostic labs toward compliance with global standards. While regulations raise barriers for new entrants due to validation and data integrity requirements, they also enhance reliability, patient safety, and trust, thereby supporting the long-term growth of advanced diagnostic technologies.

Substitution risk in brain cancer diagnostics remains low to moderate. While traditional imaging modalities like MRI, CT, and PET are widely available, they cannot fully substitute molecular profiling, which provides essential tumor subtyping and prognostic insights. Similarly, liquid biopsy is emerging as a complementary tool but is not yet robust enough to replace tissue-based biopsy for primary diagnosis. Instead, substitutes act more as adjunctive technologies, reinforcing the multimodal approach rather than replacing core diagnostic platforms, ensuring continued demand across modalities.

End User concentration is moderate, with adoption spread across hospitals, cancer specialty centers, diagnostic laboratories, and academic research institutes. Large academic medical centers dominate uptake of molecular diagnostics, given their advanced infrastructure and access to complex cases. Community hospitals rely more on imaging and outsourced testing. As reimbursement expands, adoption is expected to spread into mid-tier hospitals and regional diagnostic labs. This fragmented yet specialized demand ensures a diverse customer base, but vendors often prioritize partnerships with top-tier institutions to showcase cutting-edge technologies.

Technique Insights

The imaging segment dominated the brain cancer diagnostics market with the largest revenue share of 53.18% in 2024. Modalities such as Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Positron Emission Tomography (PET) remain indispensable for initial diagnosis, surgical planning, and monitoring disease progression. Among these, MRI is considered the gold standard, particularly for glioblastomas, astrocytomas, and metastatic brain lesions, offering unparalleled soft-tissue contrast and tumor localization capabilities.

The dominance of imaging arises from its universal accessibility and clinical necessity. Unlike molecular or liquid biopsy assays, which may be limited by infrastructure or reimbursement, MRI and CT are widely available in hospitals and diagnostic centers worldwide. Imaging is often the first-line diagnostic tool, performed immediately after the presentation of neurological symptoms. Furthermore, technological advancements - such as functional MRI, diffusion tensor imaging, and hybrid PET-MRI systems - have enhanced diagnostic precision and enabled real-time visualization of tumor physiology.

Leading companies such as GE Healthcare, Siemens Healthineers, and Philips Healthcare continue to innovate with AI-enabled platforms, workflow automation, and integration of radiomics. As brain tumors frequently recur and require continuous monitoring, imaging maintains its position as the backbone of the diagnostic continuum, ensuring it remains the dominating segment.

Molecular diagnostics represents the fastest-growing segment in the brain cancer diagnostics industry, projected to register the fastest CAGR through 2030. This acceleration is driven by the integration of genomic and epigenomic profiling into global clinical guidelines, transforming how tumors are classified and managed. The 2021 WHO CNS classification mandates biomarker testing for mutations such as IDH1/2, 1p/19q codeletion, and MGMT promoter methylation, making molecular diagnostics indispensable for precise subtyping and treatment decisions.

A major growth driver is the adoption of DNA methylation profiling, which provides an objective molecular “fingerprint” of tumors, surpassing the limitations of morphology-based diagnosis. Studies have shown that traditional pathology misclassifies up to 14% of tumors, highlighting the clinical necessity for molecular tools. Platforms from Illumina, Thermo Fisher Scientific, and Roche Diagnostics are widely used for sequencing, PCR-based assays, and methylation analysis, while emerging technologies like liquid biopsy (ctDNA, exosomes) are gaining traction for recurrence monitoring.

Product Insights

The reagents & consumables segment dominated the brain cancer diagnostics industry with the largest revenue share of 52.64% in 2024, driven by their recurring use in every diagnostic workflow. This category includes biopsy kits, PCR reagents, sequencing consumables, immunohistochemistry stains, and DNA methylation arrays, all of which are indispensable for accurate tumor profiling. Unlike capital-intensive instruments that are purchased once and used for years, consumables generate continuous demand, translating into strong and predictable revenue streams.

The increasing reliance on molecular diagnostics and precision oncology is a major driver. The WHO’s classification of CNS tumors now requires biomarker testing for IDH mutations, MGMT promoter methylation, and 1p/19q codeletion, each test consuming reagents. DNA methylation profiling, rapidly gaining clinical adoption, further accelerates consumables’ dominance. Additionally, liquid biopsy assays for circulating tumor DNA (ctDNA) and exosomes are emerging as minimally invasive options for glioblastoma recurrence monitoring, further expanding this segment.

Leading companies, including Illumina, Thermo Fisher Scientific, Roche Diagnostics, and Agilent Technologies, have strategically expanded their consumable portfolios tailored to oncology applications. With the growing incidence of brain tumors, high recurrence rates, and the need for repeated testing throughout a patient’s care journey, consumables remain the backbone of market revenues and the most commercially valuable segment.

Software & AI solutions represent the fastest-growing product segment, expected to expand at a double-digit CAGR between 2025 and 2030. The rise of artificial intelligence, machine learning, and digital pathology is transforming brain cancer diagnostics by enhancing accuracy, speed, and standardization. These solutions complement imaging and molecular platforms by reducing diagnostic variability and providing clinical decision support.

AI-enabled tools for MRI and PET scan interpretation can distinguish tumor progression from treatment-related effects, a challenge that often confounds radiologists. Platforms such as Philips IntelliSpace, Siemens AI-Rad Companion, and PathAI are increasingly integrated into hospital workflows. Additionally, AI-powered digital pathology systems enable precise tumor classification, while bioinformatics software streamlines the interpretation of next-generation sequencing and methylation profiling results.

The scalability and interoperability of AI solutions make them especially attractive to healthcare systems under cost and efficiency pressures. Cloud-based analytics, integration with electronic health records, and predictive algorithms for prognosis are further broadening adoption. While still smaller in revenue compared to consumables and instruments, Software & AI Solutions are rapidly reshaping the competitive landscape, creating opportunities for partnerships between medtech, diagnostics, and digital health companies. This positions the segment as the most dynamic growth driver of the market.

Cancer Type Insights

The gliomas segment dominated the brain cancer diagnostics industry with the largest revenue share of 55.04% in 2024. Within this category, glioblastoma multiforme (GBM) is the most aggressive and common form, known for its poor prognosis and high recurrence rates. The complexity of gliomas demands frequent imaging, biopsy, and molecular profiling, driving sustained demand for diagnostic tools. MRI remains the gold standard for glioma diagnosis and monitoring, with advanced techniques such as functional MRI and diffusion-tensor imaging providing critical surgical planning insights. At the molecular level, markers like IDH mutation, 1p/19q codeletion, and MGMT methylation are essential for classification and treatment decision-making, reflecting WHO’s 2021 CNS tumor guidelines.

Because gliomas are nearly impossible to cure and require lifelong monitoring, patients undergo multiple imaging and biomarker tests over the disease course. This recurrent need makes gliomas the most commercially significant segment for diagnostics. Companies like GE Healthcare, Siemens Healthineers, Illumina, and Roche Diagnostics are heavily focused on solutions targeting glioma diagnosis. With high prevalence, diagnostic intensity, and limited therapeutic breakthroughs, gliomas dominate the revenue share in the cancer-type segmentation.

Pituitary tumors represent the fastest-growing cancer type segment in the brain cancer diagnostics market. Though often benign, their rising detection rates are linked to the increased availability of advanced MRI systems and greater awareness among clinicians and patients. These tumors are frequently discovered incidentally during imaging for unrelated conditions, reflecting both improved access to neuroimaging and advancements in diagnostic precision. Unlike gliomas or meningiomas, pituitary tumors have a higher likelihood of effective management, but accurate diagnosis is essential to differentiate them from more aggressive tumors and to guide treatment. Functional pituitary adenomas, which secrete hormones such as prolactin or ACTH, require molecular and biochemical testing alongside imaging, driving multidimensional diagnostic demand.

Technological progress in high-resolution MRI, PET tracers, and endocrine biomarker assays has accelerated growth in this segment. Furthermore, the adoption of AI-based image analysis is improving the early identification of microadenomas that were previously difficult to detect. From a market perspective, while pituitary tumors represent a smaller base compared to gliomas, their rapid CAGR is fueled by increasing prevalence, routine health screening, and the growing role of integrated imaging-molecular diagnostics. This makes pituitary tumors the most dynamic growth contributor within the cancer-type segmentation.

End Use Insights

Hospitals represent the largest share of the brain cancer diagnostics market, driven by their central role in comprehensive cancer care. Most patients first present to hospitals with neurological symptoms such as seizures, vision disturbances, or headaches, where diagnostic imaging such as MRI, CT, and PET-CT is conducted. Hospitals also serve as the primary point of biopsy collection and pathology evaluation, making them indispensable to early and accurate diagnosis. Their advanced infrastructure reinforces the dominance of hospitals, access to multidisciplinary teams, and integration of imaging, molecular, and surgical services under one roof. In both developed and emerging regions, tertiary care and academic hospitals act as referral hubs for brain tumor diagnostics. Additionally, hospitals are often the first adopters of AI-enabled imaging tools, liquid biopsy platforms, and advanced sequencing assays, making them critical to the adoption of next-generation diagnostics.

Given their broad patient base, ability to handle complex cases, and reimbursement-driven test adoption, hospitals remain the most commercially significant end user group. Their high testing volumes and established procurement budgets ensure they will continue to dominate revenues in the brain cancer diagnostics industry.

Oncology treatment centers are emerging as the fastest-growing end user segment, fueled by the increasing need for specialized cancer care. Unlike general hospitals, these centers focus exclusively on oncology, offering cutting-edge diagnostics, targeted therapies, and clinical trial participation. Their specialization makes them ideal early adopters of molecular diagnostics such as DNA methylation profiling, next-generation sequencing (NGS), and liquid biopsy assays, which are becoming essential for brain cancer classification and monitoring. These centers are particularly attractive for patients seeking second opinions, personalized medicine, and access to experimental treatments. With the expansion of private oncology networks in North America, Europe, and Asia-Pacific, more patients are choosing specialized centers over traditional hospitals.

Furthermore, oncology centers often collaborate with biotech companies and research institutions, integrating advanced imaging and biomarker tests into clinical trials. This positions them at the forefront of adopting disruptive diagnostic technologies, such as AI-driven pathology platforms and digital biomarker solutions. Although their current market share is smaller compared to hospitals, the high CAGR is driven by a patient preference for specialized care, precision diagnostics integration, and strong partnerships with diagnostic innovators. This makes oncology treatment centers the fastest-expanding end user segment.

Regional Insights

North America dominated the brain cancer diagnostics market, accounting for 41.9% of global revenue in 2024, supported by advanced healthcare infrastructure, widespread access to MRI and PET-CT systems, and strong reimbursement frameworks. The U.S. in particular leads due to high glioblastoma incidence, extensive clinical trials, and the early adoption of molecular diagnostics such as DNA methylation profiling and NGS panels. Europe follows closely with Germany, the UK, and France, driving adoption through strong cancer research institutions and favorable reimbursement policies.

U.S. Brain Cancer Diagnostics Market Trends

The U.S. leads the global brain cancer diagnostics industry, supported by advanced healthcare infrastructure, strong reimbursement frameworks, and early adoption of molecular profiling. The country is a hub for innovations in AI-driven imaging, liquid biopsy, and DNA methylation assays. High incidence of glioblastoma and extensive clinical trial activity further drive demand, while collaborations between academic centers, biotech firms, and diagnostic players accelerate innovation and market expansion.

Europe Brain Cancer Diagnostics Market Trends

The Europe brain cancer diagnostics industry is shaped by increasing disease prevalence, earlier screening initiatives, and strong adoption of advanced imaging. Growth is reinforced by the integration of AI in MRI/CT, the expansion of molecular and genomic profiling, and the rising interest in liquid biopsy. Hospitals remain key users, while demand accelerates for precision, minimally invasive, and real-time intraoperative diagnostic tools.

The UK brain cancer diagnostics market benefits from the National Health Service (NHS) integration of advanced imaging and biomarker diagnostics. National programs emphasize early cancer detection and equitable access, making MRI and molecular diagnostics more accessible. Increased adoption of precision oncology, strong academic research, and government-backed initiatives like Cancer Research UK enhance diagnostic uptake. Rising collaborations with biotech and AI imaging firms also contribute to making the UK a growing hub for advanced brain cancer diagnostics.

The brain cancer diagnostics market in Germany stands out in Europe with robust healthcare spending and a strong diagnostics ecosystem. Advanced neuroimaging adoption is widespread, while German research institutions, notably the DKFZ, pioneered DNA methylation profiling, now integrated into WHO guidelines. Strong reimbursement for innovative diagnostics supports the adoption of NGS and AI-driven imaging. Germany’s emphasis on precision oncology, translational research, and public-private partnerships makes it a leader in brain cancer diagnostics innovation within Europe.

Asia Pacific Brain Cancer Diagnostics Market Trends

The Asia Pacific brain cancer diagnostics industry is estimated to showcase the fastest CAGR of 9.18% over the forecast period due to increasing healthcare reforms, rising incidence of brain cancer, significant R&D investments in brain cancer therapies, and advancements in imaging technologies. Moreover, the rapid increase in population serves as another factor contributing to the growth of the regional market. The growth is fueled by expanding healthcare infrastructure, government-backed cancer control programs, and increasing adoption of precision oncology in China, Japan, and India.

The China brain cancer diagnostics market is the fastest-growing, driven by rising cancer incidence, expanding healthcare infrastructure, and government investments in precision medicine. Increased availability of MRI and PET-CT systems, combined with rapid adoption of NGS and liquid biopsy technologies, is accelerating diagnostic adoption. Domestic biotech and AI imaging startups are thriving, supported by government-backed cancer programs. Urban centers drive market growth, though access disparities remain between top-tier cities and rural areas.

The brain cancer diagnostics market in Japan is characterized by rapid adoption of molecular and imaging technologies, supported by a highly advanced healthcare system. The government actively promotes cancer screening and early diagnosis under its national cancer control programs. High prevalence of gliomas and strong academic-industry collaborations have fueled demand for NGS, methylation profiling, and digital pathology. Japan also leads in AI-enabled MRI interpretation, making it a regional innovation hub.

Latin America Brain Cancer Diagnostics Market Trends

Latin America shows growing demand for brain cancer diagnostics, led by Brazil and Mexico. The market is expanding due to improving healthcare infrastructure, increased MRI and CT installations, and government-led cancer awareness initiatives. While reimbursement gaps limit the adoption of advanced molecular diagnostics, partnerships with international players and clinical trial activity are expanding access. Brazil, in particular, is investing in oncology centers that integrate molecular profiling and AI solutions.

The Brazil brain cancer diagnostics market dominates Latin America, driven by rising cancer incidence and an expanding network of oncology centers. MRI and CT adoption is high in urban areas, while private hospitals increasingly integrate molecular profiling and biomarker testing. Collaborations with global diagnostic firms are improving access to advanced assays, though rural disparities persist. Government cancer initiatives and private sector investments make Brazil the regional growth leader.

Middle East and Africa Brain Cancer Diagnostics Market Trends

The Middle East and Africa region is in the early stages of brain cancer diagnostics adoption, with disparities in access between high-income Gulf States and low-resource African countries. The Gulf region, led by the UAE and Saudi Arabia, is investing in advanced MRI, PET-CT, and molecular platforms, while much of Africa still relies on basic imaging. International collaborations, government investments, and medical tourism are driving growth in this emerging market.

The Saudi Arabia brain cancer diagnostics market is emerging as a key market in the Middle East, with rapid investments in healthcare infrastructure under Vision 2030. The country is expanding access to advanced MRI and PET-CT scanners, while tertiary hospitals adopt molecular diagnostics and NGS panels for cancer classification. Collaborations with Western biotech firms and growing medical tourism support market growth. Government-backed cancer awareness programs further accelerate the adoption of brain cancer diagnostics in Saudi Arabia.

Key Brain Cancer Diagnostics Company Insights

The major market players are focused on adopting strategic initiatives such as launches, mergers & acquisitions, and partnerships. Furthermore, several players are focusing on the development of testing services, thereby boosting the demand.

Recent Developments

• In February 2025, the College of American Pathologists (CAP) endorsed DNA methylation profiling as a breakthrough in tumor classification, encouraging its integration into diagnostic workflows for brain and CNS cancers.

• In March 2025, Thermo Fisher Scientific launched the Oncomine Methylation NGS Assay, advancing precision oncology by enabling targeted methylation-based sequencing for solid tumors, including brain cancers.

• In April 2025, Johns Hopkins University researchers introduced an AI-driven liquid biopsy, achieving ~75% detection rates for brain cancers from blood samples in early trials across the U.S., South Korea, and Poland.

• In July 2025, researchers at the University of Michigan and UCSF unveiled FastGlioma, an AI tool capable of detecting residual glioma tissue intraoperatively in just 10 seconds, with 92% accuracy.

• In January 2024, Imperial College London introduced TriNetra-Glio, a blood-based test capable of diagnosing glioblastoma, astrocytomas, and oligodendrogliomas non-invasively.

• In June 2024, the University of Birmingham and Newcastle University developed an AI-enabled MRI tool that detects medulloblastoma in children within 10 minutes, reducing reliance on invasive biopsies.

Brain Cancer Diagnostics Market Report Scope

Global Brain Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the brain cancer diagnostics market report based on cancer type, product, technique, end use, and region:

• Technique Outlook (Revenue, USD Million, 2021 - 2033)

  • Imaging

    • Magnetic Resonance Imaging (MRI)

    • Computed Tomography (CT) Scan

    • PET

    • Single-Photon Emission Computed Tomography (SPECT) Scan

  • Tissue Sampling / Biopsy

  • Molecular Diagnostics

  • Others

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Instruments & Systems

  • Reagents & Consumables

  • Software & AI Solutions

• Cancer Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Gliomas

  • Meningiomas

  • Pituitary Tumors

  • Others

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospitals

  • Oncology Treatment Centers

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait